-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Benzinga·07/24/2026 18:41:39
Listen to the news
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.